Coagulation Factor V is an essential component of the prothrombinase complex, which activates the zymogen prothrombin to thrombin. A patient was described who developed a Factor V inhibitor that neutralized the procoagulant activity of Factor V and resulted in a fatal hemorrhagic diathesis (Coots, M. C., A. F. Muhleman, and H. I. Glueck. 1978. Am. J. Hematol. 4:193-206). This inhibitor was shown to be an IgG antibody that bound to the light chain of Factor V. Using a series of light chain deletion mutants, we have found that this antibody binds to the second C-type domain of the light chain. Both inhibitor IgG and Fab fragments rapidly neutralized the procoagulant activity ofFactor Va, implying that the neutralization resulted from specific binding to the C2 domain. We have previously demonstrated that deletion of the C2 domain results in loss of procoagulant activity, as well as loss of phosphatidylserine-specific binding. Confirming these results, both inhibitor IgG and Fab fragments interfered with phosphatidylserinespecific binding of Factor V. Conversely, preincubation of Factor Va with procoagulant phospholipids protected the cofactor from inactivation by the inhibitor. Our results suggest that this inhibitor neutralizes the procoagulant activity of Factor Va by interfering with the C2-mediated interaction with phospholipid surfaces, thereby disrupting formation of the prothrombinase complex. (J. Clin. Invest. 1992. 90:2340-2347
Introduction
Acquired coagulation factor inhibitors are pathologic immunoglobulins that specifically bind to coagulation factors and either neutralize their procoagulant activity or result in their clearance from the circulation (1) . These inhibitors may develop as alloantibodies in patients who have congenital deficiencies and receive replacement therapy, or, more rarely, as autoantibodies in patients with no known previous factor defi-A preliminary report ofthis work was presented at the national meeting of the American Federation of Clinical Research, Baltimore, MD on ciency. Acquired inhibitors have been most frequently reported in patients with autoimmune disorders or lymphoid malignancies, and during pregnancy (2) . Most of these inhibitors are directed against Factor VIII, although patients with inhibitors directed against von Willebrand factor, Factor V, Factor IX, Factor XI, and Factor XIII have been reported (3) . Factor V inhibitors are relatively rare and have been most frequently reported in the postsurgical setting and/or in association with aminoglycoside antibiotics (3) . Several recent reports, however, have described patients developing Factor V inhibitors after exposure to topical bovine thrombin preparations during cardiovascular or neurosurgical procedures (4, 5) . In one report, the topical thrombin preparation was shown to contain bovine Factor V, which may have served as the immunogen in that patient (4) .
Although coagulation Factors V and VIII share considerable structural and functional homology (6), the incidence, clinical presentation, and course associated with inhibitors to these two cofactors are quite different (2, 3) . The bleeding associated with acquired Factor VIII inhibitors is often severe and life-threatening, with the sudden development of large hematomas, retroperitoneal bleeding, and/or cerebral hemorrhagic events (2) . Although some of these inhibitors resolve without specific treatment (7), many require aggressive medical intervention, including plasmapheresis and cytotoxic therapy ( 1, 8 ) . On the other hand, acquired Factor V inhibitors appear to be more variable in their presentation, with many patients presenting with prolonged clotting times but without clinically significant bleeding. Most Factor V inhibitors are low in titer, and they frequently resolve spontaneously without specific treatment (3) . Whether the observed clinical differences between acquired inhibitors to Factors V and VIII are a reflection of the much lower concentration of Factor VIII in plasma (Factor V, 10 ,tg/ml; Factor VIII, 0.2 ,ug/ml) (6) or other mechanisms of inhibition is unknown. Since -20% of circulating Factor V is stored in platelet a-granules, it has been suggested that this Factor V may be inaccessible to inhibitors, and thereby account for the more benign course frequently seen in these patients (3) . For this reason, platelet transfusions have been recommended as a treatment for hemorrhage in patients with Factor V inhibitors (9) , although not all patients respond to this intervention (4, 10) . A subset of patients with Factor V inhibitors have had fatal outcomes despite aggressive supportive treatment (10, 11) . The best characterized case was reported by Coots et al. ( 11 ) in 1978. This inhibitor was shown to be an IgG4X ( 12) that bound to the light chain ofFactor Va ( 13, 14) , and blocked platelet surface prothrombin activation and Factor Xa binding ( 13) .
Our laboratory is using site-directed mutagenesis to study structure-function relationships in coagulation Factor V. Factor V is an essential component of the prothrombinase com-plex, which activates prothrombin to thrombin (6) . Analysis of the primary structure of Factor V reveals that it is a mosaic protein containing several types of homologous internal repeats (6) (Fig. 1) . We The recombinant Factor V deletion mutants used in this study were prepared from the Factor V cDNA (16) (Fig. 1 ). All mutants were transiently expressed in COS cells and collected in serum-free bovine albumin-supplemented conditioned media, as previously described ( 16) . The construction, expression, and structural and functional characterization of the following mutants have been described elsewhere:
rHFV des C2, rHFV des C I C2, rHFV des LC, rHFV des A3C 1, rHFV HC, and rHFV LC ( 15) . In addition to these six deletion mutants, we have also constructed two additional mutants that were used in this study. The mutant rHFV A3, which lacks amino acids 1-1545 and 1878-2196, was constructed by ligating the 5'-noncoding region and the signal sequence of the Factor V cDNA to the cDNA encoding for the third A-type domain. The polymerase chain reaction (PCR) was used with the Factor V cDNA as the template and the oligonucleotides 5'-CACAATCGATGTCGACTCCGGGCTGTCCCAGCTCG-3' and 5'-ACACGGTACCACTGTGCCGCTTCTGTCCCTT-3' as primers to produce a fragment containing nucleotides 1-167 ofFactor V with a 5'ClaI site and a 3'KpnI site. After restriction with ClaI/KpnI, this fragment was ligated to a KpnI/HindIII restriction fragment from rHFV des CIC2, containing nucleotides 4785-5792 and a TAG stop codon, and a ClaI/HindIII restriction fragment of pBluescript. After DNA sequence analysis of the PCR fragment, the construct was released from pBluescript with Sall and subcloned into the SalI site of pDX, as previously described ( 16) . The mutant rHFV C2, which lacks amino acids 1-2036, was constructed with a BglII/SalI restriction fragment of pDX, containing all of the expression vector except for 100
bp, a BglII/ KpnI restriction fragment ofpDX rHFV LC containing the remaining nucleotides ofpDX and nucleotides 1-167 ofFactor V, and a KpnI/SalI restriction fragment of pDX rHFV des A3C1, containing nucleotides 6270-6903 of Factor V. As with the other deletion mutants, these were transiently expressed in COS cells and characterized by immunoprecipitation analysis and for Factor V procoagulant activity, as previously described ( 15, 16) . None of these Factor V deletion mutants possessed procoagulant activity comparable to plasma or recombinant Factor Va. ELISA analysis. Conditioned media containing rHFV and deletion mutants were analyzed using the biotinylated immunoaffinitypurified rabbit polyclonal anti-human Factor V antibody, as previously described ( 16) . To epitope map the inhibitor, an ELISA microtiter plate (Costar EIA, Cambridge, MA) was coated with a 1:250 dilution of total patient IgG overnight at 4°C. The plate was subsequently blocked with PBS containing 0.2% Tween-20 and 0.25% (wt/ vol) nonfat dry milk (blocking buffer). The wells were then incubated with 50-Ml aliquots of conditioned media containing rHFV or the individual deletion mutants. Bound Factor V (or deletion mutant) was detected using the rabbit polyclonal anti-human Factor V antibody ( 16) .
Immunoprecipitation ofrecombinant Factor V and Factor V mutants. Immunoprecipitation analysis of [35S]methionine metabolically labeled recombinant Factor V deletion mutants was performed as previously described ( 16) . For epitope mapping ofthe inhibitor, patient IgG ( 1:500 dilution) was substituted for the polyclonal rabbit anti-human Factor V in the immunoprecipitation step with Protein A Sepharose. Factor V activity assays. Factor Va procoagulant activity was measured using a chromogenic assay, as previously described ( 16) . Briefly, the Factor V sample was first activated with RVV-V (3.75 Ag/ml) and added to 50 mM Tris HCl, pH 7.9, 175 mM NaCl, 5 Aliquots ofthe reaction mixture were transferred to microtiter plate wells, and the amount of thrombin generated during the reaction was determined by the addition of0.2 mM S2238 (D-Phe-L-pipecolyl-Arg-p-nitroanilide) and measuring the change in absorbance at 405 nm using a V.,, microtiter plate reader (Molecular Devices, Inc., Menlo Park, CA). Standard curves were prepared using purified thrombin.
The effect ofthe inhibitor on the procoagulant activity of Factor Va was characterized by several approaches. To determine if the inhibitor was time-dependent, 50 Ml of rHFV ( 1 .5 Mg/ml) in conditioned media was activated with RVV-V and diluted 1:3 into buffer A containing 5 mM CaCI2. The sample was then divided into two 50-M1 aliquots, and 4 Ml of an I l-,ug/ml sample of patient IgG was added to one tube. The reaction mixtures were incubated at 370C and samples (5 1A (15) .
In addition to examining the subtype by ELISA, we also coupled the monoclonal subclass antibodies for anti-human IgG, IgG,, and IgG4 to CNBr-activated Sepharose 4B using the manufacturer's recommended procedure. To determine which subclass specific antibody could functionally clear the inhibitor, 40 Ml of a 1:20 dilution of the patient IgG fraction in Buffer A was incubated with 10 Ml of the antibody-coupled beads for2 h at 4C. The beads were removed by centrifugation, and the supernatants were tested for residual inhibitory activity in the chromogenic assay (0.9 nM RVV-V rHFVa incubated with -13.4 nM nonbinding patient IgG for 5 min at 22°C before assay). The beads were then washed and the bound IgG eluted with 0.1 M glycine, pH 2.5. Following removal of the beads by centrifugation, the pH was neutralized with one-tenth vol 2.0 M Tris-HCl, pH 8.0, and assayed for inhibitory activity.
Phospholipid binding assay. The solid-phase ELISA used to detect the binding of Factor V and the deletion mutants to phospholipids has been previously described (15) . Briefly, phosphatidylserine (PS) or phosphatidyicholine (PC) dissolved in methanol (3 Mg/ml) were airdried in the wells ofa microtiter plate. The wells were then blocked with 50 mM Tris-HCI, 150 mM NaCl, pH 7.2, containing 5 mg/ml gelatin, for 1 h at 37°C, washed, and then incubated with 50 Ml aliquots of conditioned media containing recombinant Factor V or a specific deletion mutant. Detection was performed using the biotinylated immunoaffinity-purified polyclonal rabbit anti-human Factor V antibody ( 15 This inhibitor was previously reported to comprise -50% of the patient's total IgG ( 13). When we investigated the effect of dilution on inhibitory activity, we found that a twofold molar excess of patient IgG to rHFVa resulted in < 50% residual procoagulant activity, and a fourfold molar excess resulted in < 20% activity (Fig. 2) . When the molar ratio of inhibitor to Factor V was further increased to > 10-fold, the procoagulant activity ofFactor Va was completely neutralized, since the reaction proceeded at approximately the same rate in the absence of Factor Va.
To determine if the inhibitory effect of the antibody was secondary to the specific structural epitopes recognized or to steric hindrance from the Fc portion of the immunoglobulin, we prepared and isolated Fab fragments from the inhibitor. These Fab fragments produced a similar inhibitory pattern on dilution (Fig. 2) . Furthermore, the inhibitory curve was shifted to the right by a factor of two, consistent with the fact that IgG is a bivalent molecule, whereas the Fab fragment is univalent. As with IgG from normal pooled plasma, papain-generated Fab fragments from normal pooled plasma IgG were noninhibitory at 1,000-fold molar excess (data not shown).
Subtype analysis. The inhibitor was originally reported to be an IgG4 subclass ( 12) . During the course of our experiments, however, we obtained data that was inconsistant with this interpretation. We therefore reevaluated the subclass of this inhibitor using two different methods and confirmed these results using plasma obtained directly from the laboratory that originally described the inhibitor. When we coated microtiter plate wells with subclass-specific murine anti-human IgGs, we found that the Factor V-binding fraction was an IgG, heavy chain subclass (Fig. 3 a) . Furthermore, murine anti-human Figure 3 . Inhibitor IgG subtype analysis. The inhibitor subtype was determined by two separate methods. In (a), microtiter plate wells were coated with murine subtype-specific anti-human IgG antibodies and, after blocking, were incubated with patient plasma. The wells were then incubated with recombinant Factor V, and binding of Factor V was detected using the biotinylated polyclonal anti-human Factor V. This ELISA was performed twice, using two separate murine anti-human IgG4 clones. In (b), murine subtype-specific antihuman IgG antibodies were coupled to CNBr-activated Sepharose CL4B beads and incubated with aliquots of patient IgG. The beads were removed by centrifugation, and the supernatant was assayed for residual Factor Va inhibitory activity in the prothrombinase chromogenic assay, as described in the legend to Fig. 2 . The CL4B column represents control glycine-blocked CNBr-activated Sepharose CL4B
beads.
IgG, antibodies coupled to Sepharose CL4B beads were capable of clearing the inhibitory activity from the patient IgG fraction, confirming that the IgG1 heavy chain subclass contained the Factor V inhibitor (Fig. 3 b) . When bound antibody was eluted from the beads, the eluent from the coupled anti-IgG, beads possessed Factor Va neutralizing activity (data not shown). Murine anti-IgG4 subclass antibodies neither bound Factor V in the ELISA, nor did they clear the neutralizing activity from the patient IgG fraction (Fig. 3) . The inhibitor was previously reported to be a monoclonal IgG paraprotein, as determined by preparative isoelectric focusing, but independent studies have reported conflicting results, with one study describing the paraprotein as an IgGX and another study as an IgGK. The heavy chain subclass ofthe paraprotein has not been directly determined. We reexamined the patient's paraprotein by serum protein electrophoresis and confirmed the presence ofa small monoclonal component that comprised -30% of the total gamma region (data not shown). Immunofixation analysis revealed two monoclonal components including IgGX and IgMX, as well as a possible IgMK component (data not shown). The observed IgM paraproteins were unrelated to the Factor V inhibitor, since all of the inhibitor bound to Protein A Sepharose. The low ratio of IgG to Factor V that fully inhibits Factor V function suggests that the IgG paraprotein represents the inhibitor. However, the limited amounts of patient plasma available to us were not sufficient to define the gamma chain subclass of paraprotein or to directly demonstrate binding ofthe paraprotein to Factor V.
Epitope mapping ofthe Factor V inhibitor. Previous studies with this inhibitor revealed that it bound to the light chain of Factor Va ( 14, 19). We have further localized the epitope(s) recognized by this inhibitor by using a series of recombinant light chain deletion mutants ofFactor V (Fig. 1) . When microtiter plate wells were coated with patient IgG, the only Factor V constructs that bound significantly were rHFV, rHFV des A3C1, and rHFV LC (Fig. 4) . Conversely, those constructs that lacked the second C-type domain (rHFV des C2, rHFV des ClC2, and rHFV des LC) did not bind (Fig. 4) . The background absorbance was higher than we normally observe in our ELISA, which was caused by residual patient Factor V bound to the Protein A Sepharose purified inhibitor (data not shown). Therefore, to confirm the ELISA, we also used the inhibitor to immunoprecipitate [35S] methionine metabolically labeled recombinant deletion mutants (Fig. 5) . As with the ELISA, this confirmed that the inhibitor specifically recognized the C2 domain of Factor V, since mutant constructs lacking the C2 domain were not immunoprecipitated by the inhibitor. Furthermore, the presence ofthe Cl domain was not necessary for recognition of the C2 domain by the inhibitor, since the individual C2 domain as well as the C2 domain linked to the B domain (from thrombin-activated rHFVa des A3C 1) were immunoprecipitated by the inhibitor (Fig. 5, lanes 12 Inhibition ofphosphatidylserine-specific binding. Although the patient plasma samples studied possessed no measurable Factor V procoagulant activity, we did find antigenic Factor V by ELISA at a concentration approximately halfthat in pooled human plasma (data not shown). This indicates that the inhibitor is a neutralizing antibody and that the Factor V present in patient plasma is in a functionally neutralized immune com- Figure 4 . Epitope mapping of inhibitor by ELISA analysis. Microtiter plate wells were coated overnight with the inhibitor IgG ( 1:250 dilution into PBS). The plates were then blocked and then incubated with the following deletion mutants: rHFV (88 ng/ml), rHFV des C2 (98 ng/ml), rHFV des C1C2 (107 ng/ml), rHFV des LC (94 ng/ml), rHFV des A3C1 (118 ng/ml), rHFV LC (83 ng/ml), and conditioned media from mock-transfected COS cells. The plates were then washed and the same biotinylated polyclonal antibody that was used to determine the concentrations was used to detect binding to the inhibitor. Background absorbance from the mock-transfected conditioned media was 0.55 absorbance units, which was subtracted from the total absorbance of each mutant to determine specific binding. The precipitated proteins were then electrophoresed on 5-10% gradient SDS-polyacrylamide gels and visualized by autoradiography.
The Factor V samples immunoprecipitated were lanes 2 and 8, rHFV HC; lanes 3 and 9, rHFV LC; lanes 4 and 10, thrombin-activated rHFV des C2; lanes 5 and 11, rHFV A3; lanes 6 and 12, rHFV C2; lanes 7 and 13, thrombin-activated rHFV des A3C 1. Lane I contains the molecular weight standards, and lane 14 contains the control rabbit IgG immunoprecipitate, which contains only the 270-kD contaminant seen in variable amounts in all of our conditioned media samples from COS cells ( 16) .
plex with the inhibitor. When we investigated whether the Factor V in patient plasma was capable ofbinding to immobilized phosphatidylserine, however, we found that phosphatidylserine-specific binding was significantly decreased in comparison to binding to the polyclonal anti-Factor V antibodies. Almost 90% of the antigenic Factor V in a 1: 100 dilution of pooled human plasma bound to the immobilized phosphatidylserine, while < 20% of the antigenic Factor V in a similar dilution of patient plasma was capable of binding to phosphatidylserine. This observation suggested that inhibition of PS-specific binding of Factor V may, at least in part, result in the functional neutralization observed in vivo and in vitro.
We have previously shown that removal of the second Ctype domain of Factor V results in the loss of procoagulant activity and phosphatidylserine-specific binding (15) . To investigate the effect of the inhibitor on PS-specific binding of Factor V, we preincubated the inhibitor IgG or Fab with rHFV before a phospholipid binding assay. Similar to the inhibition of procoagulant activity, the inhibitor decreased PS-specific binding of Factor V by -40% at a twofold molar excess of inhibitor to rHFV (Fig. 6) . The Fab fragments produced a similar inhibitory curve, again shifted to the right similar to the inhibition of procoagulant activity (Fig. 6) . In contrast to the inhibitor's effects on procoagulant activity, however, neither the intact inhibitor nor the Fab fragments were capable ofcompletely inhibiting the binding of Factor V to immobilized PS. Even at a greater than 100-fold molar excess ofinhibitor or Fab to Factor V, there was still 20-25% residual binding of Factor V to PS (Fig. 6) . Conversely, when we first incubated the 2344 Ortel, Quinn-Allen, Charles, Devore-Carter, and Kane Factor V with immobilized phosphatidylserine for 1 h and then exposed the bound Factor V to a -500-fold molar excess of inhibitor, there was no decrease in the amount ofbound Factor V (data not shown). This suggested that once Factor V was found to anionic phospholipids, at least in the phospholipid binding assay, it could not be dissociated by the inhibitor. The inhibitor and/or Fab fragments were also capable of blocking binding of rHFVa, rHFV des A3C 1, and rHFV LC to immobilized phosphatidylserine (data not shown). These results confirmed that the inhibitor was interfering with phosphatidylserine-specific binding mediated by the C2 domain. In contrast, neither total IgG nor papain-generated Fab fragments from pooled human plasma inhibited the phosphatidylserinespecific binding of recombinant Factor V (data not shown).
Protective effect of phospholipids on Factor Va activity. Since the preceeding results suggested that the inhibitor may be interfering with the procoagulant activity ofFactor V by blocking PS-specific binding, we investigated whether preincubation of Factor Va with phospholipids would protect the cofactor from neutralization by the inhibitor. When Factor Va was preincubated with rabbit brain cephalin before exposure to the inhibitor, the procoagulant activity was protected from neutralization (Fig. 7 ) . In fact, a > 10-fold increase in the molar ratio of inhibitor to Factor Va was necessary to obtain a comparable level of functional neutralization. A similar protective effect was observed when Factor Va was preincubated with rabbit brain cephalin before exposure to the Fab fragment. In contrast, preincubation with either prothrombin or Factor Xa alone, at the concentrations used in the prothrombinase assay, did not protect Factor Va from the neutralizing effect of the inhibitor (data not shown).
Discussion
Coagulation Factors V and VIII are circulating procofactors that interact with their respective enzyme complexes to localize and amplify a procoagulant response to endothelial injury (6, 20 Factor VIII inhibitors have been extensively studied and many have been epitope-mapped to sites within the heavy or light chain of the cofactor (21) . Inhibitors that bind to the heavy chain have been localized to the amino-terminal of the A2 domain (21) , or to epitopes between the Al and A2 domains (21, 22) . Inhibitors that bind to the light chain have been predominantly localized to the C2 domain ofFactor VIII, although some light chain inhibitors that bind to the A3 and/ or C1 domains have also been described (21 ) . In contrast to inhibitors that bind to the heavy chain, inhibitors that recognize light chain epitopes (specifically, the C2 domain) interfere with phosphatidylserine-specific binding of Factor VIII (23) . Furthermore, preincubation of Factor VIII with phospholipids has been shown to prevent the neutralization of Factor VIII procoagulant activity by inhibitors directed against the light chain (23, 24). Presumably, therefore, these inhibitors disrupt the binding of Factor VIII to a phospholipid membrane or platelet surface, and thereby interfere with the formation of Factor Xa by the "Factor X-ase complex."
In contrast to Factor VIII inhibitors, most Factor V inhibitors have not been characterized beyond the initial studies necessary to establish a diagnosis. Chiu et al. (25) phosphatase conjugated inhibitor was blocked by Factor Xa, suggesting that this inhibitor may interfere with the interaction between Factor Va and Factor Xa (25). Zehnder and Leung (4) described a 65-yr-old man who developed antibodies to bovine thrombin and bovine and human Factor V after exposure to a topical thrombin preparation during a porcine mitral valve heterograft. Immunoblot analysis revealed the inhibitor bound to the light chain of Factor V (4), but no studies were performed to elucidate how the inhibitor may be interfering with the procoagulant activity of Factor Va. Lastly, the Factor V inhibitor that forms the basis of this report developed in a 51-yr-old man 10 d after an exploratory laparotomy ( 11 ).
This antibody was also shown to bind to the light chain of Factor Va ( 14, 19), and Annamalai et al. ( 14) observed that the binding of alkaline-phosphatase conjugated inhibitor to immobilized Factor Va was blocked by Factor Xa, suggesting the presence of a Factor Xa binding site in the light chain. Furthermore, this inhibitor was shown to interfere with the Factor Va-mediated binding of Factor Xa to the platelet surface, although whether this was caused by interference with the Factor Va-platelet interaction or the Factor Va-Factor Xa interaction was not determined ( 13). We did not observe a protective effect of Factor Xa in our prothrombinase assay, however, although this most likely represents differences in the assays used (see below).
Although this antibody was initially reported to be an IgG4 subtype ( 12) (26) . This patient's course was relatively brief, however, and we do not know the precise timing when the individual samples were obtained.
Our data indicates that this antibody binds to the second C-type domain ofFactor V and effectively neutralizes its procoagulant activity. The inhibitor is capable of binding to the intact (unactivated) molecule as well as the isolated domain, suggesting that the epitope is exposed before procofactor activation. Furthermore, the inhibitor IgG as well as papain-generated Fab fragments interfere with phosphatidylserine-specific binding, and rabbit brain cephalin is able to protect the activated cofactor from neutralization by the inhibitor, suggesting that the inhibitor and procoagulant phospholipids bind at overlapping or spatially adjacent sites. These results confirm and extend our previous studies, which demonstrated that the C2 domain of the Factor V light chain was capable of mediating the specific binding of Factor V to immobilized phosphatidylserine ( 15) . Factor VIII inhibitors that bind to the C2 domain of Factor VIII also block binding ofFactor VIII to immobilized phosphatidylserine (23) . Taken together, these observations suggest novel strategies for both the treatment of Factor V and Factor VIII inhibitors, as well as the development ofnew anticoagulant agents that specifically interfere with cofactor function.
The fact that this inhibitor did not completely block binding of Factor V to immobilized phosphatidylserine at concentrations that completely neutralized procoagulant activity suggests that there may be subtle differences in the binding of Factor V to immobilized phosphatidylserine compared to rabbit brain cephalin in solution. The binding ofFactor V to phospholipid vesicles and platelets most likely involves more than the C2-mediated interaction with phosphatidylserine alone, since Mann et al. have identified and characterized a region within the third A-type domain of the light chain of bovine Factor V that binds to phosphatidylserine-containing phospholipid vesicles (27, 28) . Furthermore, Factor V and Factor VIII do not appear to compete for binding to the platelet surface (29) , suggesting that more than anionic phospholipids are required for specific cofactor binding. Alternatively, it is possible that the inhibitor may also be disrupting other interactions in addition to the Factor V-phospholipid interaction. The factor
Va light chain appears to contain at least a portion of the high affinity binding sites for Factor Xa and calcium (25, 30) . We did not observe a protective effect when Factor Va was preincubated with Factor Xa prior to exposure to the inhibitor in the chromogenic prothrombinase assay, however. The absence ofa protective effect under these conditions may be a reflection of the significantly weaker association between Factor Xa and Factor Va in the absence of phospholipids (31 ) . Consistent with this weaker interaction, the concentrations of Factor Xa that were reported by Annamalai et al. ( 14) to block binding of inhibitor to immobilized Factor Va were several hundredfold higher than those employed in our study. We did observe that preincubation ofFactor Va with rabbit brain cephalin and Factor Xa results in an increased protective effect compared to preincubation with rabbit brain cephalin alone (Ortel, 
